Tag

Ulcerative Colitis

All articles tagged with #ulcerative colitis

Abivax shares rise on reassuring safety data for UC drug as NDA looms
business21 days ago

Abivax shares rise on reassuring safety data for UC drug as NDA looms

Abivax’s late‑stage data on obefazimod show malignancies at rates consistent with ulcerative colitis background risk, easing prior cancer concerns and sending the stock up about 34%; the company reiterates plans to file an FDA NDA in Q4 2026, with a Crohn’s trial due mid‑2027 and roughly 37% of initial non‑responders achieving remission after ~10 months on 50 mg. Analysts like Jefferies call the update supportive but warn that generalist investors may still hesitate amid cancer risk, cash needs, and takeover chatter.

Merck’s TL1A-targeted antibody tulisokibart secures remission in UC Phase 3 induction trial
health29 days ago

Merck’s TL1A-targeted antibody tulisokibart secures remission in UC Phase 3 induction trial

Merck's tulisokibart, an anti-TL1A monoclonal antibody, met the Phase 3 ATLAS-UC induction-only study’s primary endpoint of clinical remission (Modified Mayo Score at week 12) and key secondary endpoints in adults with moderately to severely active ulcerative colitis, with no safety concerns reported. This marks the first successful Phase 3 remission signal for an anti-TL1A therapy, and results will be presented alongside data from the ongoing Study 1 and shared with regulatory authorities, highlighting the approach's potential against immuno-fibrosis.

Abivax UC drug delivers strong remission in Phase 3, but safety signals spark caution
healthcare1 month ago

Abivax UC drug delivers strong remission in Phase 3, but safety signals spark caution

Abivax’s ulcerative colitis therapy obefazimod showed high remission rates in a 580-patient Phase 3 maintenance trial, with about 51% remission at both 25 mg and 50 mg doses over 44 weeks versus 10.4% with placebo, suggesting strong efficacy. However, the company reported a few cancer cases among treated patients, raising safety concerns and sending shares lower after the results were disclosed.

Stool biomarkers and meat intake may forewarn IBD flares, study suggests
health5 months ago

Stool biomarkers and meat intake may forewarn IBD flares, study suggests

A large UK study (PREdiCCt) of over 2,600 people with inflammatory bowel disease found that higher baseline fecal calprotectin, a noninvasive stool marker of gut inflammation, strongly predicted future flares even when patients were symptom-free—UC patients with elevated calprotectin faced about a 34% objective flare risk within 2 years vs ~11% with low levels. Habitual meat intake was linked to nearly double the risk of ulcerative colitis flares, while other dietary factors showed no consistent associations; there was no such meat-flare link for Crohn’s disease. The results point to a potential for biomarker- and diet‑guided, personalized IBD management, using stool tests plus dietary data to forecast relapses months ahead. However, the study is observational and cannot prove causation, and local validation may be needed before widespread adoption.

health5 months ago

35-year-old mum survives bowel cancer after long ulcerative colitis battle

A 35-year-old Texas mother with a long history of ulcerative colitis is diagnosed with an aggressive colorectal cancer after childbirth. She undergoes three surgeries to remove her large intestine and reconstruct a J-pouch, followed by a six-month chemotherapy course; she has remained cancer-free since 2013 and reports a markedly improved quality of life despite ongoing dietary adjustments.

Smoking's Gut Bacteria Link Offers New Hope for Ulcerative Colitis Treatment
health10 months ago

Smoking's Gut Bacteria Link Offers New Hope for Ulcerative Colitis Treatment

Researchers have discovered that smoking produces metabolites like hydroquinone that promote mouth bacteria such as Streptococcus to grow in the gut, which can reduce inflammation in ulcerative colitis. This finding suggests potential treatments using probiotics or prebiotics to mimic smoking's protective effects without the associated health risks.

Understanding the Fundamentals of Inflammatory Bowel Disease
health10 months ago

Understanding the Fundamentals of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), affecting up to 3.1 million adults in the U.S., is a chronic condition where the immune system attacks the intestines, causing inflammation and damage. Diagnosis involves medical history, physical exams, lab tests, and imaging like endoscopy or MRI. IBD differs from irritable bowel syndrome (IBS), which has similar symptoms but no underlying disease. Managing IBD requires a team approach to find effective medication and lifestyle strategies to prevent flare-ups and address related health issues.

Mouth-to-Gut Bacterial Migration May Explain Smoking's Benefits for Ulcerative Colitis
health11 months ago

Mouth-to-Gut Bacterial Migration May Explain Smoking's Benefits for Ulcerative Colitis

Research shows that smoking helps alleviate ulcerative colitis by promoting mouth bacteria like Streptococcus to grow in the gut, triggering an immune response that reduces inflammation. This effect is linked to metabolites like hydroquinone produced during smoking, which could lead to alternative treatments such as probiotics or prebiotics, avoiding smoking's health risks.

"Dad, 34, Diagnosed with Colon Cancer After Ulcerative Colitis Flare: Exclusive"
health2 years ago

"Dad, 34, Diagnosed with Colon Cancer After Ulcerative Colitis Flare: Exclusive"

Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. The experience prompted him to advocate for informed consent in his treatment and cherish time with his family. Inflammatory bowel disease patients should be vigilant about symptoms and undergo regular colonoscopies due to the increased risk of colorectal cancer.

"Dad's Ulcerative Colitis Flare Unveils Colon Cancer Diagnosis"
health2 years ago

"Dad's Ulcerative Colitis Flare Unveils Colon Cancer Diagnosis"

Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. His experience highlights the increasing incidence of colon cancer in young people, particularly those with inflammatory bowel disease, and the importance of regular colonoscopies for early detection.

"Pfizer's VELSIPITY Receives EU Approval for Inflammatory Bowel Disease Treatment"
health2 years ago

"Pfizer's VELSIPITY Receives EU Approval for Inflammatory Bowel Disease Treatment"

Pfizer's drug Velsipity, used to treat ulcerative colitis, has been approved by the European Commission for patients aged 16 or older who did not respond well to previous treatments. The approval, based on successful late-stage trials, allows the drug to be available in all 27 EU countries. With an estimated 2.6 million people in Europe living with ulcerative colitis, Velsipity is expected to compete with Bristol Myers Squibb's Zeposia and has also sought regulatory approvals in other countries.

"Saffron Supplements: A Promising Solution for Ulcerative Colitis Inflammation"
health2 years ago

"Saffron Supplements: A Promising Solution for Ulcerative Colitis Inflammation"

Researchers from Howard University presented a study suggesting that saffron supplements may reduce inflammation and improve clinical manifestations in people with ulcerative colitis. The study involved participants receiving low or high doses of saffron or a placebo for 8 weeks, with those taking high doses showing significant improvement in clinical scores and inflammatory biomarkers. Saffron also led to a decrease in harmful bacteria and an increase in beneficial bacteria in the gut. While promising, the use of saffron for IBD should be assessed on a case-by-case basis and may not be suitable for everyone.

"Palisade Bio's PALI-2108 Shows Promise, Stock Surges 150%"
health-and-medicine2 years ago

"Palisade Bio's PALI-2108 Shows Promise, Stock Surges 150%"

Palisade Bio presented positive preclinical data of its lead program PALI-2108 at the 2024 Crohn’s & Colitis Congress, demonstrating its safety, local activity, and low systemic exposure for the treatment of moderate-to-severe ulcerative colitis. The orally delivered and colon-activated PALI-2108 is advancing toward a Phase 1 clinical study expected to commence in 2024, with promising outcomes including colon-specific distribution, dose-dependent efficacy in a mouse UC model, and no systemic toxicity in dogs, offering potential for revolutionizing UC treatment.